Pfizer Inc.'s new rare disease franchise Vyndaqel/Vyndamax (tafamidis) got off to a strong start, surprising investors by generating notable revenues in its first full quarter on the market. Management had set low expectations for initial uptake of the first-in-class transthyretin stabilizer, indicated for treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), because of low diagnosis rates.
Vyndaqel generated $79m in the US and $156m worldwide, the company reported in its third quarter financial report on 29...
